ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On April 27, 2017, ANI Pharmaceuticals,Inc. (ANI, we, or us)
issued a press release announcing that we will release our first
quarter 2017 financial results on Thursday, May 4, 2017, before
the opening of the U.S. financial markets. We will host a
conference call with the investment community at 10:30am, Eastern
Time on May 4, 2017. A copy of the press release is furnished as
Exhibit99.1 to this report.
In accordance with General Instruction B.2. of Form8-K, the
information in this Current Report on Form8-K, including
Exhibit99.1, shall not be deemed to be filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, and shall not be incorporated by reference into any
registration statement or other document filed under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such
filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| No. | Description | |
| 99.1 | Press release, dated April 27, 2017, issued by ANI |
About ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP)
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet. ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Recent Trading Information
ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) closed its last trading session 00.00 at 53.11 with 242,091 shares trading hands.
